OCT in Diagnosis of Irregular Corneas
Oregon Health and Science University · NCT03504800
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 14–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 445
- US sites recruiting
- 1
- Study start
- May 1, 2018
- Record last updated
- September 9, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions.
The primary goal will be achieved by using optical coherence tomography (OCT) to:
- Develop an OCT-based system to classify and evaluate corneal-shape irregularities.
- Develop OCT metrics for more sensitive detection of keratoconus progression.
- Develop OCT-and-topography guided phototherapeutic keratectomy (PTK) for irregular corneas.
Being studied: Optical Coherence Tomography
Conditions: Keratoconus; Corneal Opacity; Corneal Dystrophy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
GROUP A
- Keratoconus:
- CDVA ≥ 20/25 in the better eye; and both of the following in the worse eye
- Topography characteristic of keratoconus or pellucid marginal degeneration
- Contact lens-related corneal warpage:
- Contact lens use; and
- Topography irregularities
- Dry eye:
- Symptoms of dry eye documented by Ocular Surface Disease Index (OSDI) questionnaire score ≥ 30; and
- Topography irregularities
- Presence of punctate epithelial erosion on exam with surface staining
- Aqueous deficiency or evaporative dry eye
- Epithelial basement membrane dystrophy (EBMD):
- Negative corneal fluorescein staining; and
- Corneal opacities; and
- Topography irregularities
- Stromal addition or subtraction:
- Scars; or
- Salzmann's degeneration; or
- Stromal dystrophies; or
- Complication (visual complaints) after LASIK or photorefractive keratectomy (PRK)
- Stromal distortion:
- Radial keratectomy (RK); or
- Corneal transplants.
- Normal controls:
- Healthy eyes with no previous eye procedures/surgeries.
GROUP B
Participants will be selected from the keratoconus population in Group A based on topography findings.
GROUP C
Participants will be selected from the stromal addition/subtraction and stromal distortion populations of Group A if they have vision primarily limited by scars, dystrophy, or high astigmatism that could benefit from PTK.
Exclusion Criteria (all groups):
- Inability to give informed consent.
- Inability to maintain fixation for OCT imaging.
- Inability to commit to required study visits.
- Eyes with concurrent cataract, retinal disease, glaucoma, or other eye conditions that may limit the visual outcome after surgery.
- Previous corneal surgeries if considered as a keratoconus participant.
- Pregnancy or breastfeeding.
Recruiting US locations
Humberto Martinez
Portland, OR 97239
Site contact: Humberto Martinez, COT · 503-494-7712 · martinhu@ohsu.edu
Study contacts (from the official record)
- Humberto Martinez, COT · 503-494-7712 · martinhu@ohsu.edu
- Denny Romfh, OD · 503-494-4351 · romfhd@ohsu.edu
Similar studies in Oregon
All healthy volunteers studies in Oregon →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Bend, OR + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1/Phase 2
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 20–49
- RecruitingHealthy volunteersEarly Phase 1
Monoferric for Prenatal Iron Deficiency
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 18–65 · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Portland, OR + 55 other US sites
- Eligibility basics
- Ages 18–79